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THE EFFECTS OF AGE OR SEX ON CHONDROGENESIS OF HUMAN MSCS 
ELAINE BURKE 
ABSTRACT 
 
Introduction: Stem cells have become promising treatments for osteoarthritis due to the 
cells’ ability to regenerate cartilage and availability from bone marrow. Various studies 
have established the chondrogenic potential of human marrow stromal cells (hMSCs) 
upon treatment with transforming growth factor β1 (TGF-β1), yet the difference in 
potential between cells derived from young subjects and those derived from elder 
subjects has not been confirmed.  
 
Objectives: This study seeks to establish whether the chondrogenic potential of hMSCs 
changes with age and sex. This study used a high-density 2D model to measure the acute 
response of hMSCs to chondrogenic induction over a short time course and various 
treatment levels. The experiments investigated the expression of chondrogenic genes and 
expression of TGF-β1 receptors (ALK5) in hMSCs after TGF-β1 treatment to determine 
whether pediatric hMSCs have more potential for chondrocyte differentiation than adult 
hMSCs. 
 
Methods: With IRB approval, nine bone marrow samples were obtained from discarded 
tissue of adults undergoing total hip replacement and juveniles requiring bone graft for 
alveolar cleft repair. Subject ages ranged from age 8 to 66. Low-density mononucleated 
cells were cultured in plastic tissue culture dishes. Adherent hMSCs were expanded in 
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monolayer culture with phenol red-free α-MEM medium with 10% fetal bovine serum. 
After 48 hours of treatment with TGF-β1, cells were collected for RNA extraction and 
RT-PCR analysis of chondrogenic genes and TGF-β1 receptor levels. Alcian blue 
staining in 24-well plates of hMSCs was performed after 10 days to compare the effects 
of different concentrations of TGF-β1, and the effects of another inducer of 
chondrogenesis, kartogenin (KGN) on matrix accumulation. 
 
Results: Gel electrophoresis of PCR products revealed no consistent trend in 
chondrogenic mRNA expression in pediatric cells compared to adult cells, or female cells 
compared to male cells. The data indicate that the change in chondrogenic potential of 
hMSCs with age and sex is inconsistent. KGN showed no consistent effect on hMSCs. 
Cells with high baseline levels of TGF-β1 receptor (ALK5) showed no upregulation of 
ALK5 after TGF-β1 treatment, while samples with low basal expression of TGF-β1 
receptors showed upregulation after TGF-β1 treatment. 
 
Conclusions: There is still much debate in the literature regarding the potential of adult 
hMSC chondrogenesis compared to juveniles. This study confirms the irreproducibility 
of displaying differences between young and adult hMSCs. A larger sample size is 
needed to establish a correlation between age and chondrogenic potential. Further in vitro 
studies will consider the optimum time course and concentration of TGF-β1 to observe 
differences in gene expression of cells, and will identify other clinical determinants of 
differentiation potential.  
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INTRODUCTION 
 
Osteoarthritis (OA) is a common consequence of aging, affecting over 60% of 
adults over age 65 in North America and Europe (Martel-Pelletier 2016). As life 
expectancy increases, OA is expected to become more prevalent in elderly populations 
and increase all-cause mortality (Lane 2017). Current treatments for OA primarily treat 
symptoms by reducing pain and increasing joint function through medication or joint 
replacement. Despite these treatments, no direct cure has been established (Martel-
Pelletier 2016). Regenerative therapies have been promising, but few studies have 
demonstrated their long-term viability. Understanding the mechanisms of bone and 
cartilage senescence can lead to better treatments for OA and other age-related diseases.  
 
Stem Cells and Cartilage 
One way to evaluate the properties of tissue aging is to study mesenchymal stem 
cells (MSCs) and their lineages (Figure 1). MSCs can be isolated from bone marrow and 
induced to differentiate into mesenchymal tissues (Pittenger 1999). Osteoblasts, 
chondrocytes, and adipocytes all arise from MSCs, also known as human marrow stromal 
cells (hMSCs) to specify stem cells obtained from bone marrow from those derived from 
other tissues (Lindner 2010). Marrow stromal cells adhere to plastic and differentiate into 
the trilineage displayed under the influence of different agents (Dominici 2006). These 
properties render hMSCs useful for experimental studies of cartilage regeneration and 
aging.  
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Figure 1. Differentiation of MSCs into tissue-specific lineages.  
 
Cartilage is abnormal in OA, wherein chondrocytes are unable to self-regenerate 
and repair (Loeser 2009). The cells become catabolic, degrading the articular cartilage 
matrix and increasing pro-inflammatory chemicals as a stress response (Zhou 2016). 
Because chondrocytes lose anabolic function and cannot generate viable replacements, a 
treatment able to produce functional cells in vivo could be a sustainable treatment for 
patients with OA. Stem cells are an appealing candidate for this function. MSCs act as a 
reserve of replacement cells for damaged tissues (Caplan 2006). If the cells were injected 
at the site of cartilage damage and stimulated to induce chondrogenesis, hMSCs could 
restore cartilage functionality.  
 
Mesenchymal 
Stem Cell
Transitory 
Chondrocyte
Chondrocyte
Hypertrophic 
Chondrocyte
Transitory 
Preadipocyte
Transitory 
Osteoblast
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Effect of TGF-β1 on hMSCs 
To commit hMSCs to the chondrogenic lineage, marrow stromal cells are 
stimulated by transforming growth factor β1 (TGF-β1) when the cells are grown at high 
density (Zhou 2004). TGF-β1 regulates human chondrocytes by stimulating signals for 
differentiation, extracellular matrix formation, and cell proliferation (Finnson 2008).  
The optimal environment for this process is serum-free medium containing 
dexamethasone, ascorbate-2-phosphate, insulin, sodium pyruvate, and TGF-β1 
(Johnstone 1998). To mimic embryogenic development of cartilage, cell-cell contact is 
critical for hMSC differentiation in vitro (Boeuf 2010). Therefore, a density of cells is 
necessary for chondrogenesis in all induction models. 
The degree of chondrogenesis stimulated by TGF-β1 can be quantified by 
assessing gene expression levels through RNA extraction, or by analyzing cartilaginous 
matrix accumulation through alcian blue staining of glycosaminoglycans.  
 
Effect of KGN on hMSCs 
  Another promoter of chondrocyte differentiation from hMSCs is kartogenin 
(KGN). KGN induces hMSC differentiation into chondrocytes and protects chondrocytes 
from degradation due to OA (Johnson 2012). Similar to treatment with TGF-β1, KGN is 
most effective on cells grown in serum-free DMEM at high density (Johnson 2012). 
KGN is another tool that could be used to analyze differentiation of hMSCs and possibly 
treat OA through intra-articular KGN administration. 
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Age-Dependent Changes in Differentiation 
 The age-related decrease of differentiation potential has been demonstrated for the 
osteoblast lineage (Mueller 2001). Because studies showed that human marrow cells from 
older subjects have decreased potential for differentiation to bone-forming osteoblasts 
(Zhou 2008), it is possible that older subjects would also show a decrease chondrocyte 
renewal. However, reports on the age-related decrease in chondrogenic potential are 
limited.  
 Bovine studies showed a decrease in chondrogenic potential of adult MSCs 
compared to juvenile MSCs (Erickson 2011). The difference observed, however, was 
much more significant in bovine cells compared to previous studies with human 
chondrocytes. In a study comparing age differences in chondrocyte proliferation and 
chondrogenic potential, TGF-β1 was found to reduce the age-related differences in 
proliferation (Barbero 2004). Yet these studies do not explain or establish age-related 
changes in hMSC chondrogenesis. 
 
Scharstuhl’s Study 
In a study of hMSC chondrogenesis induced by TGF-β3, no correlation was found 
between increasing age and the chondrogenic potential of hMSCs (Scharstuhl 2007). The 
authors found that sufficient hMSCs can be differentiated in the chondrogenic lineage 
independent of age. However, the report methods may not be sufficient for this 
conclusion for several reasons. First, the study did not use pediatric cells; the minimum 
age used was 43. This gap between the subject ages may not be an appropriate measure 
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for age comparison. Studies comparing the age-related changes of chondrocytes typically 
used pediatric cells to establish differences between young and adult chondrocyte 
response to growth factors (Smeriglio 2014).  
Further, Scharstuhl’s study analyzed the degree of differentiation after 21 days of 
treatment with chondrogenic induction medium. As chondrocytes differentiate, they 
synthesize type II collagen and proteoglycans (Dexheimer 2016). In vitro, upon 
maturation, chondrocytes hypertrophy instead of being maintained as articular cartilage 
as they would in vivo, and chondrogenesis slows (Pelttari 2006, Dexheimer 2016). Matrix 
mineralization occurs by day 14 (Dexheimer 2016). Scharstuhl’s study evaluated 
chondrogenesis after 21 days—past the point of hypertrophy and matrix formation. At 
this time point, the cells may have reached the same peak chondrogenic potential because 
they have become surrounded by matrix and thus unable to continue proliferation and 
differentiation. An analysis of differentiation potential over a shorter time course is 
necessary to determine age-related differences in chondrogenesis. 
 Scharststuhl’s study provides a 3D model of chondrogenic differentiation. Use of 
different methods would strengthen his conclusion that human marrow-derived cells do 
not show an age-related decrease in chondrogenic potential. Yet his study utilized only 
one model. The medium used for hMSC tissue culture consisted of DMEM, MCDB-201, 
ITS, dexamethasone, ascorbate-2-phosphate, antibiotics, FCS, epidermal growth factor, 
and platelet-derived growth factor BB. This is not a standard medium for hMSC 
expansion because FCS and FBS formulations are inconsistent across batches (Chase 
2010). This variability reduces the accuracy of age-related comparisons between hMSCs. 
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The induction medium consisted of DMEM high glucose, antibiotics, L-glutamine, 
sodium-pyruvate, ascorbate-2-phosphate, dexamethasone, ITS, proline, and 10 ng/mL 
TGF-β3. The reagents in this medium are optimized stimulators for differentiation and 
mineralization (Chase 2010). The hMSCs may have been overstimulated to the degree 
that the difference between the chondrogenic potentials was obscured. With a smaller 
stimulus and shorter time course, it is possible that age-related differences in hMSC 
differentiation abilities may be detectable. 
The authors claimed no correlation between mRNA profiles and subject age. 
However, the data shows that aggrecan was upregulated over 100-fold and type II 
collagen 1,000-fold in the hMSCs of both younger and older subjects compared to the 
control. Type I collagen was downregulated much more significantly in the 69-year-old 
sample. There are clear differences in the subjects’ mRNA that the authors did not 
address. 
Scharstuhl’s study optimizes the differentiation of hMSCs into chondrocytes by 
using a stimulating medium and a lengthy time course to show that viable hMSCs can be 
obtained from elder subjects and used for chondrogenesis. Cells from elder, osteoarthritic 
populations were shown to be sufficiently capable of differentiation into chondrocytes. 
While it may be that adult hMSCs have similar chondrogenic potential to juvenile 
hMSCs when stimulation is maximized, age-related differences in potential may be 
revealed at a lower intensity of induction. 
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Specific Aims 
As a test to determine the acute response to chondrogenic induction, this paper 
measured the differentiation status of hMSCs after 48 hours of treatment, using a high-
density 2D model. The set of experiments investigated whether pediatric hMSCs have 
more potential for chondrocyte induction than adult hMSCs. By analyzing chondrogenic 
gene expression over various treatment levels and a shorter time course, this paper sought 
to reveal the intrinsic properties of the cells, rather than the extrinsic potential of 
differentiation.  
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METHODS 
 
Subjects 
Human marrow stem cells were obtained from femoral bone marrow discarded 
from adult subjects undergoing total hip replacements with advanced hip osteoarthritis of 
similar progression, with IRB approval (Mueller 2001). Pediatric hMSCs were obtained 
from excess iliac crest marrow used as bone grafts for alveolar cleft repairs, with IRB 
approval (Ruggiero 2016). 
 
Table 1: Subject and MSC profiles.  
Age Subject Sex Days to 
confluence 
Passage 
8 807 Female 9 3 
8 963 Female 4 2 
9 962 Male 9 2 
21 739 Male 8 10 
36 926 Male 5 1 
57 966 Female 5 1 
57 969 Male 5 2 
66 980 Female 9 2 
66 968 Male 8 4 
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Samples originated from both male and female subjects, ranging from age 8 to 66 
(Table 1). Subjects with comorbidities including cancer, rheumatoid arthritis, 
hyperthyroidism, and diabetes, as well as medications or conditions that may affect 
regulation of hormones and matrix mineralization, were excluded from the study. 
Samples from nine subjects were used with equal experimental conditions including 
medium and reagents.  
 
Cell Culture 
Low-density undifferentiated mononuclear cells were isolated by centrifugation 
on Ficoll/Histopaque 1077 (Sigma Chemical Co., St. Louis, MO); this includes a 
population of nonadherent hematopoietic cells and stromal cells capable of adherence and 
differentiation into musculoskeletal cells. The adherent hMSCs were expanded in 
monolayer culture with phenol red-free α-MEM, 10% fetal bovine serum-heat inactivated 
(FBS-HI), 100 U/mL penicillin, 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA), and 
0.5 µg/mL fungizone in 2D culture 100 mm dishes. The cells were maintained at 37°C 
and media was changed every three days. At 80% confluence, cells were sub-cultured 
into 3 dishes. Most hMSCs were used at passage 1-4. 
 
Chondrocyte Differentiation 
After the cells reached 100% confluence, the proliferation medium was replaced 
with chondrogenic medium consisting of serum-free α-MEM, 1% ITS, 10-8 M 
dexamethasone, 50 µg/mL ascorbate-2-phosphate, 40 µg/ml proline, 100 µg/mL 
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pyruvate, and antibiotics (Zhou 2008). The cells were treated with or without 1 ng/ml 
TGF-β1 in 0.1% BSA. TGF-β1 was used as a differentiation factor known to stimulate 
chondrogenesis (Zhou 2013). For the negative control, cells in chondrogenic medium 
were treated with 10 µl of 0.1% BSA. After 48 hours of treatment, RNA was isolated. 
 
RNA Isolation and Reverse Transcription  
RNA isolation was performed with Trizol (Invitrogen Life Technologies, 
Carlsbad, CA, USA). Briefly, the protocol for isolation was as follows: Add 0.2 ml 
chloroform per 1 ml Trizol. Incubate at room temperature, centrifuge, and transfer 
aqueous phase to a tube. Add 0.5 ml isopropanol per 1 ml Trizol. Incubate at room 
temperature, centrifuge, and add 1 ml 75% ethanol. Centrifuge and dry the sample in a 
centrifugation vacuum-dryer. Resuspend RNA pellets in diethyl pyrocarbonate (DEPC)-
water. Incubate at 45-55°. Determine RNA yield with GeneQuant DNA Calculator. 
For reverse transcriptase (RT), 2 µg of RNA from each isolation was reverse-
transcribed into cDNA using SuperScript II (Invitrogen Life Technologies) for 75 
minutes at 42°C, 10 minutes at 70°C, and 4°C until the next step. 
 
Semi-Quantitative Polymerase Chain Reaction 
 For polymerase chain reactions (PCR), 1 µl cDNA from RT was used in 50 µl 
PCR reactions (94°C 1 minute, 55-60°C 1 minute, 72°C 2 minutes, 72°C 6 minutes per 
cycle). For gene amplification, the PCR ran 35 cycles for AGG, 29 for GAPDH, 45 for 
SOX9, 35 for COL II, and 35 for ALK5.  
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Table 2: Primer sequences of genes for RT-PCR. 
Gene Primer sequence 
GAPDH Forward Primer: 5’ CTGACTTCAACAGCGACACC 3’ 
Reverse Primer: 5’ TAGCCAAATTCGTTGTCATACC 3’ 
AGG Forward Primer: 5’ TGAGGAGGGCTGGAACAAGTACC 3’ 
Reverse Primer: 5’ GGAGGTGGTAATTGCAGGGAACA 3’ 
SOX9 Forward Primer: 5’ AGTACCCGCACTTGCACAAC 3’ 
Reverse Primer: 5’ TCTCGCTCTCGTTCAGAAGTC 3’ 
COL II Forward Primer: 5’ GGCAATAGCAGGTTCACGTACA 3’ 
Reverse Primer: 5’ CGATAACAGTCTTGCCCCACTT 3’ 
ALK5 Forward Primer: 5’ GGGGCGACGGCGTTACAGTGTTTCTGCCAC 3’ 
Reverse Primer: 5’ TGAGATGCAGACGAAGCACACTGGTCCAGC 3’ 
 
 
Gel Electrophoresis  
 For semi-quantitative determination of gene expression, PCR products were run 
in an agarose gel. The gel was formed by combining 3 g Agarose with 150 ml Tris-
acetate-EDTA (TAE). After heating for 2 minutes and cooling to about 60°C, 5 µl 
ethidium bromide was added, and the solution was poured into a gel tray. Combs were 
used to form sample wells. The gel solidified after 30-40 minutes and was then placed in 
the electrophoresis chamber. The gel was loaded with 5 µl molecular-weight size marker 
(1 kb DNA ladder) into the first well. The subsequent wells were loaded with 20 µl of 
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PCR sample per well. DDW (without cDNA) was used for a negative control of PCR. 
The gel ran for 45 minutes at 90 V. Gel images were obtained using KODAK Gel Logic 
200 Imaging System and analyzed with KODAK Molecular Imaging Software at 
exposures 1s - 14 s (KODACK, Molecular Imaging Systems, New Haven, CT, USA). 
The product size for each gene is as follows: GAPDH 460 base pairs, AGG 300 base 
pairs, SOX9 349 base pairs, COL II 379 base pairs, and ALK5 333 base pairs. GAPDH 
was used as an internal control to normalize gene expression levels for densitometry 
comparisons. 
 
Alcian Blue Staining 
HMSCs were cultured in 24-well plates in α-MEM with 10% FBS until confluent. 
Then the proliferation medium was replaced with chondrogenic medium as described. 
Treatments were added to each row of wells as follows: 1 µl 0.1% BSA (negative 
control), 1ng/ml or 10 ng/ml TGF-β1 in 0.1% BSA, and 10 nM, 100 nM, or 1 µM KGN 
(n=4). KGN selectively induces MSC differentiation into chondrocytes (Johnson 2012). 
After 10 days, the cells were rinsed with PBS solution and fixed with 10% buffered 
formalin for 40 minutes. To stain sulfated glycosaminoglycans, the cells were rinsed with 
PBS and stained with 0.1% alcian blue in 0.1 M hydrochloric acid (HCl). After overnight 
incubation at room temperature, the staining solution was removed and the cells were 
rinsed with DDW. To obtain digital images, plates were scanned using Epson 
transparency adaptor scanner. 
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Statistical Analysis 
 The Mann-Whitney test was applied to determine the significance of parameter 
differences. To test for normality of the distribution of constitutive gene expression 
levels, the Kolmogorov-Smirnov (K-S) test was applied. For Non-Gaussian distributions, 
correlations were analyzed with Spearman test to measure rank correlation (r). 
Quantitative data was analyzed by GraphPad InStat® software (GraphPad Software, Inc., 
San Diego, CA, USA). A value of p < 0.05 was considered significant.  
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RESULTS 
 
AGG Expression 
 Aggrecan is a cartilage matrix known to be upregulated by TGF-β1 stimulation of 
hMSCs (Peltarri 2006). AGG is critical for organizing the extracellular matrix (ECM) of 
cartilage. The level of AGG expression indicates the degree of hMSC differentiation into 
chondrocytes, and points to the chondrogenic potential of each sample. 
No obvious and consistent differences in the expression of AGG between 
untreated and treated cells across each age group were visible (Figure 2). In some 
hMSCs, especially in those with high baseline amounts of expression, TGF-β1 
downregulated AGG expression (926, 962, 739). The only clear upregulation of AGG 
was in one 8-year-old female with the lowest basal expression. This invites the possibility 
that pediatric cells have a different mechanism of chondrogenesis compared to adult 
cells. This finding is supported by another 8-year-old female, which also showed 
evidence of upregulation. However, the effects of TGF-β1 on AGG expression were 
much greater on sample 807 compared to 963 (Table 3). 
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                                                    GAPDH                                      AGG 
                                                     TGF-β1                                     TGF-β1 
                                    -           +     -            + 
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Figure 2. Expression of GAPDH and AGG ± TGF-β1.       
 
AGG expression is normalized to GAPDH expression to compensate for 
variations due to artefactual differences caused by mRNA quantification, cDNA sample 
loading, and other errors. GAPDH is a housekeeping gene because it is expressed at 
nearly constant levels in all samples (Ragni 2013). While some samples appear to have 
an upregulation of AGG, quantitative analysis comparing AGG expression to GAPDH 
expression reveals minor changes in AGG expression between untreated and treated cells 
for the majority of samples (Table 3). 
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Table 3. AGG expression in hMSCs treated ± TGF-β1. 
Age Specimen AGG/GAPDH Treated/Control 
Control Treated 
8 807 0.0557 0.1881 3.377 
8 963 1.038 1.329 1.280 
9 962 1.106 0.8490 0.7676 
21 739 2.049 1.407 0.6867 
36 926 1.043 0.6350 0.6088 
57 969 0.9090 0.8440 0.9285 
57 966 0.4770 0.6210 1.302 
66 968 1.118 1.239 1.108 
66 980 0.6544 0.5461 0.8345 
 
Figure 3. AGG levels in hMSCs treated ± TGF-β1.  
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Statistical analysis confirmed the observation that there appeared to be no 
consistent upregulation of AGG in treated cells. K-S test revealed a non-parametric 
distribution. The correlation between AGG expression and age of subject was not 
significant in both the control and treated cells (r = -0.02100, p = 0.9341). There were 
marked differences in the control levels of AGG/GAPDH expression in 807, 963, and 
966, and an unexpected baseline level of chondrogenic phenotype in the control. The 
presence of AGG in the samples not treated with TGF-β1 is curious because the cells did 
not have a differentiation stimulus. It is possible that the ITS, or the combination of 
reagents in the chondrogenic medium, was enough to upregulate chondrogenic gene 
expression in the control samples. 
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ALK5 Expression 
 TGF-β1 signals are transduced through two receptors, type I (ALK5) and type II. 
ALK5 potentiates TGF-β1-induced chondrogenesis of hMSCs (Finnson 2008). 
Measuring the levels of TGF-β1 receptors in treated and untreated cells could establish 
age-related changes in receptor levels and aged-related changes in the potential to 
respond to TGF-β1.  
Treatment with TGF-β1 stimulated variable ALK5 expression in hMSCs (Figure 
4). In hMSCs with high baseline amounts of expression (966, 969, 926, 962), TGF-β1 
seemed to have no effect on ALK5 levels. Yet two samples with high baseline ALK5 
expression showed downregulation of ALK5 (963, 980). As with AGG, the hMSCs with 
the lowest basal expression of ALK5 showed the most upregulation after treatment (968, 
739, 807).  
 
 
Figure 4. Expression of ALK5 in hMSCs treated ± TGF-β1.    
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Statistical analysis confirmed no significant relation between ALK5 expression 
and age. K-S test showed a non-parametric distribution of ALK5 expression data. The 
correlation between ALK5 expression and age of subject was not significant in both the 
control and treated cells (p = 0.6066, r = 0.1302). There is no consistent age or sex 
division between the three groupings (no change, downregulation, upregulation). The 
reason behind these variations requires further inquiry into the mechanisms of signaling 
between TGF-β1 and ALK5 during chondrogenesis of young and adult hMSCs. 
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Table 4. ALK5 expression in hMSCs treated ± TGF-β1. 
Age Specimen ALK5/GAPDH Treated/Control 
Control Treated 
8 807 0.1801 1.053 5.847 
8 963 3.629 1.8771 0.5172 
9 962 2.048 1.987 0.9702 
21 739 0.1949 5.010 25.71 
36 926 2.359 2.229 0.9449 
57 969 4.368 4.012 0.9185 
57 966 3.845 4.156 1.081 
66 968 0.1397 1.176 8.422 
66 980 3.155 1.721 0.5455 
 
Figure 5. TGF-β1 receptor levels in hMSCs treated ± TGF-β1. 
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AGG and ALK5 Associations With Age 
While AGG is a marker of chondrocyte matrix formation and ALK5 is an 
indicator of TGF-β1 receptor expression, both genes can reveal the effects of hMSC 
aging on chondrogenic potential. Because AGG upregulation is potentiated by TGF-β1 
signaling via ALK5, it follows that both genes would reflect changes in hMSC 
differentiation into chondrocytes. Thus, the gene expression levels of both AGG and 
ALK5 would be similarly upregulated or downregulated with an increase in subject age. 
The data, however, reveal no significant correlation between TGF-β1 effects on 
ALK5 and effects on AGG with increasing age (r = -0.08400, p = 0.7403). K-S test 
showed non-parametric distribution.  
 
 
Figure 6. Effects of TGF-β1 on AGG and ALK5 expression. 
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 Some samples that were not treated with TGF-β1 showed expression of AGG or 
ALK5. Cartilage ECM expression in untreated cells is unexpected because the control 
hMSCs were not induced with a chondrogenic stimulus. Baseline levels of TGF-β1 
receptors in untreated cells could explain why some treated samples displayed 
upregulation of ALK5 while others did not, but there is no correlation between age and 
baseline ALK5 expression as shown in Figure 5. Further, there appears to be no relation 
between age and baseline levels of AGG and ALK5 in untreated cells (Figure 7a). K-S 
test showed a nonparametric distribution of data. Analysis confirmed no significance 
between age and baseline gene expression levels (r = 0.1281, p = 0.6125). 
 It is possible that as baseline levels of ALK5 increase, AGG baseline levels 
increase as well. Independent of age, there is no relation between baseline levels of AGG 
in untreated cells and baseline levels of ALK5 in untreated cells (Figure 7b). Even 
independent of age, the correlation between baseline levels of expression shows no 
significant relationship (r = -0.4167, p = 0.2696). 
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Figure 7a. Age versus levels of AGG and ALK5 in hMSCs treated without TGF-β1. 
 
 
Figure 7b. Levels of AGG versus ALK5 in hMSCs treated without TGF-β1. 
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COL II and SOX9 Expression 
SOX9 plays a crucial role in the initiation of stem cell chondrogenesis and the 
activation of type II collagen (Kulyk 2000). COL II, like AGG, organizes cartilage ECM. 
SOX9 and COL II expression levels are indicators of chondrogenesis because both genes 
must be activated for differentiation to occur. The genes would be coexpressed in hMSCs 
as the cells differentiate into chondrocytes. 
Contrary to expectation, no expression of SOX9 or COL II was detected in the 
treated hMSCs (Figure 8).   
 
A.   
 
B.  
 
Figure 8. Expression of SOX9 (A) and COL II (B) in hMSCs treated ± TGF-β1.       
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To eliminate possibility of error or defective primer, positive controls of 52-year-
old male chondrocytes treated with 10 ng/ml interleukin-1β (IL-1β) for 48 hours and 52-
year-old male chondrocytes treated with 10 ml of 0.1% DMSO/BSA for 48 hours 
prepared previously (Zhou 2016) were tested for SOX9 and COLL II expression (Figure 
9). 
 
 
 
Figure 9. Expression of SOX9 and COL II in chondrocytes. 
 
The absence of expression of two chondrogenic genes implies that the hMSCs did 
not in fact fully differentiate into chondrocytes. However, COL II is typically detected 
after the fifth day of differentiation after treatment with TGF-β1 (Yoo 1998), and the 
hMSCs in this experiment were treated for two days. A short time course does not 
explain the absence of SOX9 expression because RNA levels of SOX9 typically peak 
after 20-65 hours of treatment (Kulyk 2000). This again points to the possibility that the 
hMSCs did not differentiate sufficiently, but the clear presence of AGG in treated cells 
indicates otherwise. 
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Cells Visualized With Alcian Blue Staining 
 Alcian blue dyes can be used to quantify the amount of metachromatic cartilage 
matrix produced by hMSCs because the dye forms a complex with glycosaminoglycans, 
an abundant component of cartilage ECM (Terry 2000). Successful differentiation of 
hMSCs into chondrocytes would be indicated by dark blue staining of cells on the surface 
of each well. 
After 10 days of treatment with TGF-β1, no staining appeared on the 24-well 
plates. The treated and untreated cells showed no differences in appearance. The bluer 
regions seen in Figure 10 are a result of unwashed dye. Observation under the 
microscope (not shown) confirmed the absence of stained cells.  
 
A.      B. 
       
 
Figure 10. Alcian blue stains of 21M 739 (A), and 66M 968 (B). 
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The lack of cartilage ECM indicates that the hMSCs did not differentiate. One 
explanation for this failure is the method of treatment. When medium was replaced 
during the treatment time course, the cells appeared clustered and folded over into two 
layers. When replacing medium, the pipette should be oriented on the side of the well and 
not directly onto the cells.  Pipetting directly onto the middle of the well may have 
disrupted the cell density needed for ample chondrogenesis.  
Another possibility is that the cells had died before staining. Even if 
differentiation had occurred before cell death, evidence of chondrogenesis would not be 
present upon staining on day 10. 
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DISCUSSION 
 
Chondrogenic Gene Expression in Juveniles and Adults 
There is still much debate in the literature regarding the potential of adult hMSC 
chondrogenesis compared to juveniles. This study confirms the irreproducibility of 
displaying differences between young and adult hMSCs.  
The properties of chondrocytes generated the hypothesis that young hMSCs 
would have a higher differentiation potential than adult cells. Juvenile chondrocytes are 
better able to self-regenerate than adult chondrocytes, yet both age groups show similar 
expression of chondrogenic markers, despite distinct expression of other genes 
(Smeriglio 2014). AGG, SOX9, and COL II are all chondrogenic marker genes that are 
expressed variably in the hMSCs presented here. Thus, chondrogenic gene expression 
may be constant across age in hMSCs as it is constant across age in chondrocytes, even if 
there is a difference in potential. 
Comparatively, in an analysis of gene expression of specific developmental and 
reproductive pathways, juvenile chondrocytes and hMSCs were found to have a 1.5-fold 
greater upregulation compared to adult chondrocytes (Taylor 2016). Chondrocytes of 
young subjects may differentiate from hMSCs while retaining their stem cell-like 
characteristics, while chondrocytes of adult subjects may lose the regeneration and repair 
functions of hMSCs. Treatment with recombinant human CHRDL1 stimulated 
proliferation in both hMSCs and juvenile chondrocytes but not in adult chondrocytes. 
CHRDL1 did not stimulate chondrogenic gene expression in hMSCs despite the increase 
in proliferation (Taylor 2016). An underlying mechanism could explain the proliferation 
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potential of both pediatric hMSCs and chondrocytes compared to adult cells, which could 
then provide insight into aging of chondrocytes. This difference in mechanism is 
supported by 8-year-old female samples 807 and 963 that showed evidence of 
upregulation. 
In a study of chondrocyte response to growth factor, the proliferation of 
chondrocytes and the cells’ response to growth factor declined with increasing subject 
age (Guerne 1995). While other growth factors were unable to stimulate proliferation of 
cells in older subjects, TGF-β1 was successful. This has two implications: first, 
chondrocyte induction via TGF-β1 may produce results that mask the differences 
between young and adult cells because TGF-β1 is such a strong stimulator of 
chondrogenesis. Therefore, to determine age-related differences of chondrogenic 
potential, a different stimulus may be needed. Secondly, chondrocytes and hMSCs may 
have different responses to TGF-β1 because Guerne’s study was able to induce 
proliferation in older chondrocytes, while experiments outlined in this paper were unable 
to match the degree of hMSC differentiation in adults to the degree in juveniles. The 
mechanisms behind each response may lead to deeper understanding of tissue aging. 
Another study highlighting the strength of TGF-β1 used “dedifferentiated” 
chondrocytes from 1-year-old subjects (Lee 2005). The term “dedifferentiated” was used 
to describe the loss of cartilaginous phenotype – the shift of collagen II formation to 
collagen I. The authors found that TGF-β1 did not always stimulate redifferentiation of 
these cells into chondrocytes in vivo, but TGF-β1 consistently induced cartilage 
formation in vitro. In this sense, the reagent may not have practical applications to OA 
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treatment and may not reflect the aging process of cartilage due to its intense stimulation 
of chondrogenesis. Chondrocytes expressing TGF-β1 have been used to treat patients 
with osteoarthritis (Lee 2015). While cartilage function improved in patients, the study 
could not readily establish the success of the treatment. 
 
TGF-β1 Receptors 
 Previous studies showed that TGF-β1 receptor expression in bovine chondrocytes 
decreased with age (Caam 2016). Further, in a proteomic study of chondrogenesis, 
downstream targets of TGF-β1 in older subjects had diminished gene expressed upon 
induced chondrogenic differentiation compared to younger subjects (Peffers 2016). Yet 
the decreased expression of the TGF-β1 receptor in older hMSCs has not been confirmed. 
 HMSC treatment with TGF-β1 has been shown to increase levels of TGF-β1 
receptor (Lee 2017). In Lee’s experiments, hMSC treatment with TGF-β1 plus BMP7 
induced higher levels of COL II, AGG, and SOX9 expression than treatment of TGF-β1 
alone. The combination of reagents acted synergistically to increase chondrogenesis by 
upregulating both TGF-β1 receptors and BMP7 receptors (Lee 2017). Because signals 
from TGF-β1 and BMP7 to induce chondrogenesis are regulated through receptor 
expression, BMP7 may be required to upregulate TGF-β1 receptors to a measurable level. 
An experiment treating pediatric and adult hMSCs with both BMP7 and TGF-β1 could 
show effects of age on TGF-β1 receptor expression, and how the levels affect 
chondrogenesis. 
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Alcian Blue Staining 
 The cells appeared folded over after replacing the medium and treatment on Day 
4. This may have inhibited cell differentiation into chondrocytes. Additionally, to 
visualize glycosaminoglycans, cells must be sufficiently confluent to stimulate 
differentiation into chondrocytes. These factors may have contributed to the absence of 
chondrocytes in the 24-well plate treatment experiment.  
 Kartogenin has been shown to stimulate chondrocyte differentiation in cells 
treated for 72 hours in DMEM (Johnson 2012). The conditions of this thesis involved a 
different medium and longer treatment time, which could explain the lack of 
chondrocytes after 10 days.  
  
Limitations 
 The restricted availability of samples resulted in a sample size unable to 
differentiate between age groups. It is possible that a larger sample size would be able to 
make such a distinction and would give a more accurate representation of hMSC 
behavior. 
 Pediatric hMSCs are less available than adult hMSCs because surgeries providing 
discarded tissue from excess bone graft for laboratory use are infrequent. A firm 
conclusion is difficult to reach if the sample size of pediatric cells is limited. 
Additionally, all adult samples were obtained from subjects with osteoarthritis, while 
pediatric samples were obtained from subjects undergoing alveolar cleft repairs. The 
influence of OA on hMSCs cannot be ignored when establishing differences in cell 
 32 
behavior between these arthritic adults and arthritis-free juveniles. Discrepancies in 
research findings of hMSC behavior could be a result of this heterogeneity (Peffers 
2016). An ideal comparison would be between healthy adults and juveniles. However, 
obtaining discarded tissue from a healthy adult is rare and invasive. 
 The concentration of TGF-β1 used to stimulate hMSC differentiation remained 
consistent across experiments in this study. Additional experiments adjusting the dosage 
of TGF-β1 may have given more clarity to the conclusions. An analysis of how 
chondrogenic gene expression varies with both age and TGF-β1 concentration would 
establish the optimum concentration of TGF-β1 for chondrogenesis stimulation. The 
comparison would also show the optimum degree of stimulus for establishing differences 
between young and adult hMSCs. This would address the complications of Scharstuhl’s 
study discussed earlier; his study used a high concentration of TGF-β1 which may have 
obscured the discrepancies between young and adult hMSC differentiation. A 
concentration curve of TGF-β1 effects on gene expression would clearly show the dose 
dependence of chondrogenesis. The differences between young and adult hMSCs may be 
evident at only certain degrees of stimulus.  
 A requirement of 2D in vitro chondrogenesis is a high density of hMSCs (Ruedel 
2013). Cell-cell contact is what facilitates chondrogenic induction (Boeuf 2010). Lack of 
sufficient density could explain the absence of glycosaminoglycans in the alcian blue 
staining, and the irreproducibility of constant gene expression levels for each age group 
in the 48-hour treatment experiments. Inconsistencies in chondrogenesis due to low 
density is evident in previous studies. Using similar methods to this paper, an experiment 
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inducing hMSC chondrogenesis via TGF-β1 failed to produce chondrocytes from hMSCs 
in monolayer cultures (Yoo 1998). However, when hMSCs were cultured in high density, 
the authors were able to initiate chondrogenesis.  
Furthermore, the 2D model does not mimic cartilage as closely as 3D pellet 
models (Peffers 2016). For future investigation of age-related differences in hMSC 
behavior, a 3D model should be explored. 
 
Future Efforts  
Reports on the effects of age on chondrogenesis have been inconsistent. This 
points to the difficulty of measuring hMCs induction into chondrocytes and the lack of 
standardized methods. A thorough study involving a larger sample size and an age 
comparison between pediatric cells and adult cells is required to reach a consensus.  
Determining the differences in signaling factors between young and adult hMSCs 
as they differentiate into chondrocytes would explain whether the differentiation 
mechanisms differ sufficiently to cause a higher degree of chondrogenic potential in 
younger cells. While these pathway differences have been studied in chondrocytes, the 
age differences of stem cells have not been established. 
 The knowledge of the role of ALK5 in chondrogenesis has room for expansion. 
To further understand the role of TGF-β1 receptors in hMSC differentiation, the 
experiments should be repeated with an ALK5 inhibitor. This would show the requisite 
receptor levels needed for TGF-β1 induction of chondrogenesis, and it may explain the 
differing levels of ALK5 in hMSCs before and after treatment. 
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Cartilage damage causes many disabilities, and cartilage therapy has yet to be 
perfected. A further understanding of tissue aging and hMSC behavior has potential to 
open new treatment possibilities. 
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